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CASE-CONTROL STUDY OF THE INTERNATIONAL EXTRANODAL LYM-
PHOMA STUDY GROUP
Sabrina Guidicelli-Nicolosi, Delvys Rodriguez-Abreu, Annarita Conconi,
Salvatore Grisanti, Armando Lopez-Guillermo, Peter W Johnson, Emilio
Montserrat, Franco Cavalli, Jean Claude Piffaretti, Emanuele Zucca
Background In regions with high prevalence of hepatitis C virus (HCV) the
frequency of this infection is higher in patients with B-cell non-Hodgkin lym-
phoma (B-NHL). Patients with HCV infection frequently show co-infections
with GBV-C (previously named hepatitis G virus) and some studies have sug-
gested the presence of higher incidence of GBV-C infection in patients with
B-NHL.
Aim Pilot study designed to test the feasibility of a future international pro-
spective study for the evaluation of the association between HCV and/or
GBV-C and B-NHL in different geographic areas.
Patients and methods 137 lymphoma cases and 125 non-lymphoma mat-
ched controls were enrolled in a pilot study case-control study conducted in
Bellinzona (Southern Switzerland), Barcelona (Spain) and Southampton
(England, UK) from July 2001 to March 2002.
Results In Switzerland (41 cases and 81 controls) the overall prevalence of
HCV was 3.3% (4.9% in NHLs) and the overall prevalence of GBV-C was
24% (22% in NHLs). In Barcelona (46 cases and 44 controls) the prevalence
of HCV was 10% (8.7 in NHLs) and the prevalence of GBV-C 20%(13% in
NHLs). There was no statistically significant difference in the frequency of
both infections between NHL patients and controls. The incidence of HCV
decreased among patients with B-NHL in Bellinzona in the last decade, from
9.4%, (as reported in a previous study by Zucca et al. Haematologica, 2000)
to 4.9%. In Southampton 50 NHL cases were analyzed, none of them resul-
ted HCV-positive, therefore no control group was analysed and GBV-C analy-
sis was not performed, too.
Conclusions Both in Southern Switzerland and in Barcelona seropositivity
rates were significantly lower for HCV than for GBV-C. HCV incidence was
significantly higher in Barcelona than in Switzerland, confirming the existence
of marked geographic differences in the prevalence of HCV in NHL but we
cannot provide any significant evidence for an association between HCV
and/or GBV-C and B-cell NHL in the studied populations. 
